ecancermedicalscience

Case Report

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib

30 May 2022
Shubham Tomar, Lakhan Kashyap, Akhil Kapoor

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant syndrome associated with fumarate hydratase (FH) gene mutation leading to defective DNA double-strand break repair mechanism. Although these tumours have an aggressive presentation, they respond well to targeted therapy with fewer adverse effects. Here we present a case of a 42-year-old female having isolated renal cell carcinoma, papillary type 2, carrying a mutation in the FH gene without cutaneous and uterine involvement. Her tumour responded well to erlotinib and bevacizumab combination and she was on treatment for 23 months. This report adds to the current literature and can help to define treatment protocols for HLRCC.

Related Articles

Miguel Araujo-Meléndez, Mirza Jacqueline Alcalde-Castro, Andrea De-la-O-Murillo, Thierry Hernandez-Gilsoul, Enrique Soto-Perez-de-Celis, Roberto Gonzalez-Salazar, Yanin Chavarri-Guerra
Atul Budukh, Sonali Bagal, Deepak Gupta, Sharyu Mhamane, Ravikant Singh, Burhanuddin Qayyumi, Abha Rani Sinha, Sanjay Kumar Singh, Satyajit Pradhan, Pankaj Chaturvedi, Rajendra Badwe, Sudeep Gupta
Camilla Engelsmann, Gitte Wooler, Vladimira Horvat, Shailesh Balasaheb Kolekar